G&E Partners’ Post

View organization page for G&E Partners, graphic

20,821 followers

Takeda inks sweet $1.2B deal with Kumquat for immuno-oncology program: Takeda has offered Kumquat Biosciences the chance to make more than $1.2 billion in a new exclusive pact that centres around an immune-oncology small molecule inhibitor. After running phase 1 trial activities Kumquat can grant Takeda global licensing rights to develop and commercialise the asset. Big Pharma Takeda will then take responsibility for all development and commercialisation activities following phase 1. Subsequently a selected program can be developed as a monotherapy, combo therapy or both. Kumquat is set to make up to $130 million in near-term payments, with additional chance to grab $1.2 billion in future clinical, regulatory and commercial milestones. Share your thoughts on the collaboration: #takeda #oncology #kumquat #biosciences #licensingdeals

Takeda inks sweet $1.2B-plus deal with Kumquat for immuno-oncology program

Takeda inks sweet $1.2B-plus deal with Kumquat for immuno-oncology program

fiercebiotech.com

To view or add a comment, sign in

Explore topics